Study Details
Design, interventions, and primary outcomes
About This Study
SGLT2 inhibitors have demonstrated to mitigate cardiorenal risk in people with type 2 diabetes and are likely to play an increasingly large role in the treatment of patients with diabetes, chronic kidney disease and hypertension. Yet the underlying mechanisms of its protective effects are incompletely understood and the salutary effect may be altered by dietary factors such as sodium intake. Therefore, carefully designed mechanistic trials are needed to better understand the interplay between ertugliflozin and salt intake and to potentially modify salt intake to maximize treatment response. In addition, the study could contribute to hypotheses concerning the effects of SGLT2 inhibitors in combination with other drugs that affect sodium homeostasis and could help to explain the differences in kidney outcomes observed in (outcome) trials, which include different ethnicities with potential differences in dietary habits.
Design
Interventions / Regimen
- Drug: ertugliflozine — SGLT2i versus placebo
- Behavioral: low salt diet — comparing low salt versus high salt diet
- Drug: placebo — placebo tablet
- Behavioral: high salt diet — high salt diet
Primary Outcomes
- Blood pressure (7 months)
Phase: PHASE4
Status: Recruiting
Start Date: 2023-07-25
Completion: 2025-12
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Collaborators: Children's Hospital Colorado
- Drug: ertugliflozine — SGLT2i versus placebo
- Behavioral: low salt diet — comparing low salt versus high salt diet
- Drug: placebo — placebo tablet
- Behavioral: high salt diet — high salt diet